Call to resolve dispute stopping 35 children receiving CF treatment
HSE and pharma firm Vertex urged by Cystic Fibrosis Ireland to resolve pricing dispute
HSE and pharma firm Vertex urged by Cystic Fibrosis Ireland to resolve pricing dispute
Cost of deal is three times annual budget usually in place for new drugs in Republic
Apporval means HSE will reimburse patients for cost of cannabis-based treatment for the first time
Debate about economic restrictions versus Covid suffering has been shirked in Ireland
Up to 1% of Co Donegal population has been estimated to have the hereditary condition
Patient’s insurer refuses to cover €40,000 cost of treatment as drug has not been approved for particular cancer
When a cure is found for Friedreich’s ataxia, will I face the long campaign to access treatment funding endured by other people with rare diseases?
HSE has agreed to reimburse Kuvan for up to 20pc of patients with rare metabolic disorder
Biogen, maker of drug to treat spinal muscular atrophy, drops price of medicine
Aidan Lyncht HSE should not be expected to pay for drugs that are not innovative
Number of indications covered by VHI initiative now 13, not three as had been thought
Move raises questions of equity between public and private patients
Consultant oncologist says inequity between public and private healthcare ‘very troubling’
Access to Medicines Ireland seeks change in R&D approach of pharmaceutical companies
Study examines access to 121 drugs approved since 2015 by EU regulator
Medicines generally blocked on basis of price as Ipha says delay ‘unacceptably long’
Spinraza is the latest in a series of controversial drugs that have put Ireland’s unique approval system in the spotlight
Cantillon: Patients have one shot at treatment but what if it is deemed too expensive?
Row between industry and body that advises the HSE over access to market for new medicines
Labour TD criticises selective provision of drug to women caught up in CervicalCheck controversy
‘It’s also important for researchers to hear what patients want from new drugs’
‘You have to ask why other countries have been happy with the clinical evidence but not here’ - mother of girl (10)
HSE representatives defend process for deciding which drugs to reimburse
Healthcare companies gave €30 million to hospitals, medical staff in 2016, says Minister
Kuvan is the only drug treatment for rare metabolic ‘heel prick test’ disorder
HSE decides against approving Translarna for reimbursement under drugs schemes
Department says it is considering three medicines for approval
Manufacturer accuses HSE of deviating from approvals processes by blocking Perjeta
More patients are switching to Long-Term Illness scheme to avoid paying charge
Over 20 emphysema sufferers to see use of ‘life changing’ Respreeza finish in two weeks
Over 20 sufferers are given Respreeza reprieve while talks continue on approving the treatment
Nellie Lannen (22 months) has condition causing muscle wastage, impaired breathing
US pharma Vertex in talks with HSE to reduce high price of cystic fibrosis drug
Negotiations with manufacturer ongoing as Harris accuses Vertex of trying to ‘extort’ taxpayers
Alpha-1 deficiency is a hereditary condition that has an “unusually high” prevalence here
Health spending in one area cannot come at expense of another
Orkambi had been ‘considered unjustifiably expensive and not sufficiently cost effective’
Taoiseach says meetings are under way with pharmaceutical firm over cost of Orkambi
Study finds the use of the ‘wonder drug’ would cost €21m over a five-year period
A third of patients with advanced renal cell carcinoma were alive five years after treatment
#YesOrkambi drive launched in support of approval for €160,000 per patient medicine
Melanoma patients told State to cover Pembro, while CF drug Orkambi ‘too expensive’
CF campaigner Orla Tinsley says decision disappointing as trials showed drug works
Pembrolizumab to be included in drugs scheme three months after economic approval
Price talks urged between Government and maker on €160,000 per patient medicine
Bristol-Myers Squibb allows compassionate access to nivolumab after appeal by Harris
Politicians are the least qualified to make call on treatment options
Numerous controversies over huge costs of drugs have erupted. What price do we put on life?
Living with PKU: Families call for genetic disorder drug that is available in UK as highly restricted diet to hard to follow
Orkambi has been described as a ‘game changer’ by health campaigners
Micheál Martin says cystic fibrosis patients will need help to pay for new drug, Orkambi
HSE says it cannot afford Orkambi which will reportedly cost €160,000 per patient per year
Initiative aimed at cost-efficient prescribing that could potentially save €15m on drugs bill
Crosswords & puzzles to keep you challenged and entertained
Inquests into the nightclub fire that led to the deaths of 48 people
How does a post-Brexit world shape the identity and relationship of these islands
Weddings, Births, Deaths and other family notices